Nichole Coleman, Ph.D.

Affiliations: 
2014 Chemistry University of California, Davis, Davis, CA 
Area:
Organic Chemistry, Medicine and Surgery
Google:
"Nichole Coleman"
Mean distance: (not calculated yet)
 

Parents

Sign in to add mentor
Heike Wulff grad student 2014 UC Davis
 (The Design, Synthesis and Functional in-vivo Evaluation of Potent and Selective Small Molecules Targeting KCa Channels.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Oliván-Viguera A, Valero MS, Pinilla E, et al. (2016) Vascular reactivity profile of novel KC a 3.1-selective positive-gating modulators in the coronary vascular bed. Basic & Clinical Pharmacology & Toxicology
Oliván-Viguera A, Valero MS, Coleman N, et al. (2015) A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Molecular Pharmacology. 87: 338-48
Coleman N, Nguyen HM, Cao Z, et al. (2015) The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 234-49
Coleman N, Brown BM, Oliván-Viguera A, et al. (2014) New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Molecular Pharmacology. 86: 342-57
Lam J, Coleman N, Garing AL, et al. (2013) The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion On Therapeutic Targets. 17: 1203-20
Strøbæk D, Brown DT, Jenkins DP, et al. (2013) NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. British Journal of Pharmacology. 168: 432-44
Bodendiek SB, Rubinos C, Trelles MP, et al. (2012) Triarylmethanes, a new class of cx50 inhibitors. Frontiers in Pharmacology. 3: 106
See more...